Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Research output: Journal article (peer-reviewed)Review article

4 Citations (Scopus)


Background: Bisphosphonates are the standard of care for treating and preventing the complications of bone metastases. Ibandronic acid is available in effective and well-tolerated oral (50 mg daily) and intravenous (6 mg via ≥ 15 min infusion every 3-4 weeks) formulations. Objectives: This paper reviews the latest preclinical and clinical data supporting the use of ibandronic acid for the prevention and treatment of the skeletal complications of neoplastic bone disease, focusing on metastatic breast cancer. The aim was to update a review of ibandronic acid published in 2004 by the current author. Conclusions: Ibandronate remains the only bisphosphonate with approved oral and intravenous formulations; ibandronate should be considered when designing a bisphosphonate-containing regimen for patients with bone metastases from breast cancer.

Original languageEnglish
Pages (from-to)3111-3119
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Issue number17
Publication statusPublished - Dec 2008
Externally publishedYes


  • Animals
  • Antineoplastic Agents/adverse effects
  • Bone Neoplasms/drug therapy
  • Clinical Trials as Topic
  • Diphosphonates/adverse effects
  • Drug Evaluation, Preclinical
  • Drug Tolerance
  • Humans
  • Ibandronic Acid
  • Pain/drug therapy
  • Intravenous
  • Efficacy
  • Ibandronic acid
  • Breast cancer
  • Oral
  • Bisphosphonates
  • Bone metastases
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update'. Together they form a unique fingerprint.

Cite this